Opko Health, Inc. and Entera Bio Ltd. Announce Abstract on Pk/Pd of Oral Glp-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 Espen Congress

Published: 2025-07-08 10:06:02 ET OPK

Published on 07/08/2025 at 10:06

OPKO Health, Inc. and Entera Bio Ltd. announced that their abstract "First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome" has been selected for a poster presentation at the 47thEuropean Society for Clinical Nutrition & Metabolism ("ESPEN") Congress, taking place September 13-16, 2025, in Prague, Czech Republic. The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera's proprietary N-Tab?? technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption.

Currently, the only approved GLP-2 agonist, which is marketed under the brand GATTEX®? (teduglutide), requires daily subcutaneous injections. Approximately 30,000 patients across the US and EU are living with SBS, and current annual sales of GATTEX®?

(tinguglutide), the only approved therapy for SBS, total roughly $800 million. SBS patients have a reduced ability to absorb nutrients and fluids and are at risk of malnutrition, unintended weight loss and additional symptoms due to the loss of essential vitamins and minerals. SBS is the most common cause of chronic intestinal failure, accounting for approximately 75% of chronic intestinal failure cases in adults and 50% of such events in children.